NCT06562647View on ClinicalTrials.gov

SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Treatment Related CancerOvarian Cancer

Interventions

DRUG

SY001

PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages

Trial Locations (1)

Unknown

RECRUITING

Linyi Cancer Hospital, Linyi

All Listed Sponsors

lead

Cell Origin Biotech (Hangzhou) Co., Ltd.

INDUSTRY

NCT06562647 - SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter